Observational study of HER2 positive rate in advanced or recurrent gastric cancer

Observational study of HER2 positive rate in advanced or recurrent gastric cancer - Observational study of HER2 positive rate in advanced or recurrent gastric cancer (JFMC44-1101)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006190

Enrollment

1200

Registered

2011-09-01

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or recurrent gastric cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically confirmed as being adenocarcinoma. 2) First diagnosed as advanced or recurrent gastric cancer since August, 2011. 3) Pathological tissue specimens and clinical information can be offered outside. 4) At least six thin sliced section (4 micron meter/slice) can be offered. 5) Written informed consent. 6) Age: 20 years or older

Exclusion criteria

Exclusion criteria: All patients who does not meet the key inclusion criteria

Design outcomes

Primary

Measure	Time frame
1) HER2-positive rate. 2) Relation among HER2-positive, HER2- negative, patient background factors, and specimen background factors. 3) Relation among HER2 Status, patient background factors, and specimen background factors. 4) Relation among overall survival, patient background factors, and treatment background factors.	—

Countries

Japan

Contacts

Public ContactYukari Kawamura

Japanese Foundation for Multidisciplinary Treatment of Cancer Office

jfmc-dc@jfmc.or.jp03-5627-7594

Outcome results